AR084498A1 - Metodos, combinaciones, apomorfina, kits, usos, capsula y dispositivo de inhalacion para tratar y/o prevenir los sintomas de la enfermedad de parkinson - Google Patents

Metodos, combinaciones, apomorfina, kits, usos, capsula y dispositivo de inhalacion para tratar y/o prevenir los sintomas de la enfermedad de parkinson

Info

Publication number
AR084498A1
AR084498A1 ARP110104270A ARP110104270A AR084498A1 AR 084498 A1 AR084498 A1 AR 084498A1 AR P110104270 A ARP110104270 A AR P110104270A AR P110104270 A ARP110104270 A AR P110104270A AR 084498 A1 AR084498 A1 AR 084498A1
Authority
AR
Argentina
Prior art keywords
apomorphine
kits
combinations
methods
parkinson
Prior art date
Application number
ARP110104270A
Other languages
English (en)
Spanish (es)
Inventor
Frazer Giles Morgan
Mark Jonathan Main
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1019291.2A external-priority patent/GB201019291D0/en
Priority claimed from GBGB1101924.7A external-priority patent/GB201101924D0/en
Priority claimed from GBGB1107454.9A external-priority patent/GB201107454D0/en
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of AR084498A1 publication Critical patent/AR084498A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP110104270A 2010-11-15 2011-11-16 Metodos, combinaciones, apomorfina, kits, usos, capsula y dispositivo de inhalacion para tratar y/o prevenir los sintomas de la enfermedad de parkinson AR084498A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1019291.2A GB201019291D0 (en) 2010-11-15 2010-11-15 Compositions and uses
GBGB1101924.7A GB201101924D0 (en) 2011-02-04 2011-02-04 Compositions and uses
GBGB1107454.9A GB201107454D0 (en) 2011-05-05 2011-05-05 Compositions and uses

Publications (1)

Publication Number Publication Date
AR084498A1 true AR084498A1 (es) 2013-05-22

Family

ID=45099135

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104270A AR084498A1 (es) 2010-11-15 2011-11-16 Metodos, combinaciones, apomorfina, kits, usos, capsula y dispositivo de inhalacion para tratar y/o prevenir los sintomas de la enfermedad de parkinson

Country Status (6)

Country Link
US (1) US20130287854A1 (OSRAM)
EP (1) EP2640374A1 (OSRAM)
JP (1) JP2013542246A (OSRAM)
AR (1) AR084498A1 (OSRAM)
TW (1) TW201304822A (OSRAM)
WO (1) WO2012066319A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104884046A (zh) 2012-10-22 2015-09-02 丝维塔斯治疗公司 用于快速缓解帕金森病的左旋多巴制剂
KR102237007B1 (ko) * 2012-10-22 2021-04-06 키비타스 테라퓨틱스, 인코포레이티드. 레보도파 혈장 농도의 환자간 변산도의 감소
WO2014074797A1 (en) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use
WO2014205031A1 (en) * 2013-06-19 2014-12-24 Map Pharmaceuticals, Inc. Sustained-release formulation of rotigotine
WO2014205030A1 (en) * 2013-06-19 2014-12-24 Map Pharmaceuticals, Inc. Pulmonary administration of rotigotine
TWI589308B (zh) 2014-03-25 2017-07-01 林信湧 一種用於治療帕金森氏症之吸入式醫藥組成物及其備製方法
MX2016013741A (es) * 2014-04-21 2017-04-06 Civitas Therapeutics Inc Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson.
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
JP7057290B2 (ja) 2016-06-27 2022-04-19 アキリオン ファーマシューティカルズ，インコーポレーテッド 医学的障害を治療するためのキナゾリン及びインドール化合物
DK3985002T3 (da) 2017-03-01 2025-08-18 Achillion Pharmaceuticals Inc Farmaceutiske aryl-, heteroaryl- og heterocyclylforbindelser til behandling af medicinske forstyrrelser
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
WO2019032685A1 (en) * 2017-08-08 2019-02-14 Robert John Petcavich FORMULATIONS FOR THE CONTRIBUTION OF TREHALOSE STIMULATING AUTOPHAGIA
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
KR20210034047A (ko) 2018-07-19 2021-03-29 임펠 뉴로파마 인코포레이티드 파킨슨 병 치료를 위한 레보도파 및 도파 데카르복실라아제 저해제의 기도 전달
JP7538113B2 (ja) 2018-08-20 2024-08-21 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体ｄ因子の医学的障害の治療のための医薬化合物
EP3840754A4 (en) * 2018-08-23 2022-09-14 Sunovion Pharmaceuticals Inc. ACID ADDITIONAL SALTS OF APOMORPHINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF USE THEREOF
CN113365617B (zh) 2018-10-16 2025-12-23 乔治亚州立大学研究基金会股份有限公司 用于医学疾病治疗的一氧化碳前药
EA202192738A1 (ru) 2019-04-12 2022-03-17 С4 Терапьютикс, Инк. Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos
EP4603484A2 (en) 2019-12-19 2025-08-20 Georgia State University Research Foundation, Inc. Compounds for the treatment of bacterial infections and potentiation of antibiotics
JP2023515073A (ja) 2020-02-20 2023-04-12 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ媒介障害の処置用のヘテロアリール化合物
CN115279370B (zh) 2020-03-05 2025-01-10 C4医药公司 用于brd9的靶向降解的化合物
JP2023538859A (ja) * 2020-08-31 2023-09-12 パーデュー、ファーマ、リミテッド、パートナーシップ レボドパ送達のための組成物及び方法
JP7787164B2 (ja) 2020-09-23 2025-12-16 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体媒介性障害の治療のための医薬化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT689438E (pt) 1993-03-26 2003-10-31 Franciscus Wilhelmus He Merkus Composicoes farmaceuticas para administracao intranasal de apomorfina
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US6193954B1 (en) 1997-03-21 2001-02-27 Abbott Laboratories Formulations for pulmonary delivery of dopamine agonists
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
GB2353222B (en) 1999-06-23 2001-09-19 Cambridge Consultants Inhalers
WO2002000197A1 (en) 2000-06-27 2002-01-03 Vectura Limited Method of making particles for use in a pharmaceutical composition
GB2364919A (en) 2000-07-21 2002-02-13 Cambridge Consultants Inhalers
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
AU2002222118A1 (en) 2000-11-30 2002-06-11 Vectura Limited Pharmaceutical compositions for inhalation
GB2375308A (en) 2001-05-10 2002-11-13 Cambridge Consultants Inhalers
WO2002089879A1 (en) 2001-05-10 2002-11-14 Vectura Delivery Devices Limited Inhalers
US20060178394A1 (en) * 2003-04-14 2006-08-10 Staniforth John N Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US20060292081A1 (en) 2003-09-15 2006-12-28 Vectura Limited Methods for preparing pharmaceutical compositions
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
WO2009147681A1 (en) * 2008-06-06 2009-12-10 Pharma Two B Ltd. Pharmaceutical compositions for treatment of parkinson's disease
GB0901520D0 (en) 2009-01-30 2009-03-11 Vectura Delivery Devices Ltd Inhaler

Also Published As

Publication number Publication date
WO2012066319A1 (en) 2012-05-24
EP2640374A1 (en) 2013-09-25
JP2013542246A (ja) 2013-11-21
US20130287854A1 (en) 2013-10-31
TW201304822A (zh) 2013-02-01

Similar Documents

Publication Publication Date Title
AR084498A1 (es) Metodos, combinaciones, apomorfina, kits, usos, capsula y dispositivo de inhalacion para tratar y/o prevenir los sintomas de la enfermedad de parkinson
PE20190914A1 (es) Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
AR084802A1 (es) Agente para mejorar el rendimiento y/o la calidad de la leche, agente para prevenir o tratar enfermedades perinatales y agente para mejorar la reproduccion en los rumiantes
Morad et al. Tamoxifen regulation of sphingolipid metabolism—therapeutic implications
BR112014031874A2 (pt) método para preparar células-tronco em concentração elevada
ECSP13013117A (es) Métodos para tratar la esclerosis múltiple y preservar y/o aumentar el contenido de mielina.
GT200900195A (es) Proceso para la preparación de acido 5- bifenil- 4- amino- 2-metil pentanoico.
BR112013019026A2 (pt) formulações farmacêuticas incluindo um composto amina
CO6410297A2 (es) Tratamiento de trastornos relacionados con la discinesia
EA201290865A1 (ru) Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
AR065837A1 (es) Composicion para el tratamiento del sindrome metabolico
CO6731103A2 (es) Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas
BR112014000843A2 (pt) Uso de picosulfato para preparação de composição intestinal para o cálculo da duração de colonoscopia, composição intestinal e kit
BR112014010586A2 (pt) aditivos para uso na preservação da madeira
BR112014013481A2 (pt) processo para a oxidação de alcanos com o uso de uma alkb alcano 1-mono-oxigenase
MX2015012547A (es) Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2.
AR088448A1 (es) Composicion para curtido ecologica
EA201391592A1 (ru) Местная композиция для лечения гиперкератотической кожи
BR112014000773A8 (pt) Composições de nicotinamida e uso terapêutico das mesmas
MX2022006161A (es) Composicion de extractos naturales con actividad antibacteriana o bacteriostatica tambien para bacterias gram negativas.
JP2017503756A5 (OSRAM)
AR073525A1 (es) Agente terapeutico contra el meteorismo para un rumiante
AR067432A1 (es) Una composicion de hidroxido de litio, un proceso para su preparacion, y un proceso para su utilizacion
Bi et al. Etudes phytochimique et pharmacologique de Bridelia ferruginea Benth (Euphorbiaceae) sur la motricité du Taenia coli de cobaye
AR084700A1 (es) Metodos de tratamiento de condiciones patologicas asociadas con vejiga hiperactiva

Legal Events

Date Code Title Description
FB Suspension of granting procedure